Search research articles
Contact Us
Filters
Showing results (51-60 of 94) with videos related to
Page
of 10
Sort By:
Genomics
|
February 1, 2022
Epigenomics analysis of miRNA cis-regulatory elements in pig muscle and fat tissues
Mingyang Hu, Renzhuo Kuang, Yaping Guo, et al.
Vaccine
|
September 4, 2025
Adopting the estimand framework in prophylactic vaccine trials
Francois Beckers, Naveen Karkada, Ye Yang, et al.
Cellular and Molecular Life Sciences : CMLS
|
November 19, 2025
Myogenic enhancer snatching promotes adipogenic differentiation during epigenetic reprogramming mediated by lineage-specific transcription factors
Mingyang Hu, Zhixiang Xu, Jiahao Sun, et al.
American Journal of Epidemiology
|
August 21, 2025
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up
Ethan Ashby, Holly Janes, Dean Follmann, et al.
Nature Communications
|
July 3, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
Chong Ma, Jiejun Du, Lan Lan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
Jaya Goswami, Jose F Cardona, Jorge Caso, et al.
Open Forum Infectious Diseases
|
December 16, 2024
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial
Dean Follmann, Xiaowei Wang, Lindsey R Baden, et al.
Expert Review of Vaccines
|
September 5, 2024
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
Frances Priddy, Spyros Chalkias, Brandon Essink, et al.
Nature Medicine
|
October 6, 2022
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Spyros Chalkias, Frank Eder, Brandon Essink, et al.
The Journal of Infectious Diseases
|
November 25, 2025
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood Samples
Dean Follmann, Lauren Dang, Eric Chu, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 94) with videos related to
Sort By:
Page
of 10
Genomics
|
February 1, 2022
Epigenomics analysis of miRNA cis-regulatory elements in pig muscle and fat tissues
Mingyang Hu, Renzhuo Kuang, Yaping Guo, et al.
Vaccine
|
September 4, 2025
Adopting the estimand framework in prophylactic vaccine trials
Francois Beckers, Naveen Karkada, Ye Yang, et al.
Cellular and Molecular Life Sciences : CMLS
|
November 19, 2025
Myogenic enhancer snatching promotes adipogenic differentiation during epigenetic reprogramming mediated by lineage-specific transcription factors
Mingyang Hu, Zhixiang Xu, Jiahao Sun, et al.
American Journal of Epidemiology
|
August 21, 2025
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up
Ethan Ashby, Holly Janes, Dean Follmann, et al.
Nature Communications
|
July 3, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
Chong Ma, Jiejun Du, Lan Lan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
Jaya Goswami, Jose F Cardona, Jorge Caso, et al.
Open Forum Infectious Diseases
|
December 16, 2024
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial
Dean Follmann, Xiaowei Wang, Lindsey R Baden, et al.
Expert Review of Vaccines
|
September 5, 2024
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
Frances Priddy, Spyros Chalkias, Brandon Essink, et al.
Nature Medicine
|
October 6, 2022
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Spyros Chalkias, Frank Eder, Brandon Essink, et al.
The Journal of Infectious Diseases
|
November 25, 2025
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood Samples
Dean Follmann, Lauren Dang, Eric Chu, et al.
Page
of 10